drugset / Trial / NCT07124013

A Study of Olomorasib (LY3537982) in Healthy Japanese Participants

NCT07124013

Phase 1 Completed 191 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to compare and see how food affects the amount of olomorasib in the blood when olomorasib is taken in two different capsule forms. Participation in the study will last approximately 6 weeks.

Timeline

Start
2025-09-16
Primary completion
2026-01-05
Completion
2026-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Olomorasib Small molecule Oral

Indications

No indication recorded.